Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders and Researchers August 15, 2023
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 14, 2023
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions August 3, 2023
Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets August 1, 2023
